- Home
- OPFI vs MDWD Comparison
OPFI vs MDWD Comparison
Compare OPFI & MDWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OPFI
- MDWD
- Stock Information
- Founded
- OPFI 2009
- MDWD 2000
- Country
- OPFI United States
- MDWD Israel
- Employees
- OPFI N/A
- MDWD N/A
- Industry
- OPFI Finance: Consumer Services
- MDWD Medicinal Chemicals and Botanical Products
- Sector
- OPFI Finance
- MDWD Health Care
- Exchange
- OPFI Nasdaq
- MDWD Nasdaq
- Market Cap
- OPFI 290.9M
- MDWD 184.8M
- IPO Year
- OPFI N/A
- MDWD 2014
- Fundamental
- Price
- OPFI $15.03
- MDWD $19.45
- Analyst Decision
- OPFI Buy
- MDWD Strong Buy
- Analyst Count
- OPFI 2
- MDWD 1
- Target Price
- OPFI $7.50
- MDWD $25.00
- AVG Volume (30 Days)
- OPFI 2.5M
- MDWD 78.0K
- Earning Date
- OPFI 03-06-2025
- MDWD 03-20-2025
- Dividend Yield
- OPFI 0.80%
- MDWD N/A
- EPS Growth
- OPFI 775.86
- MDWD N/A
- EPS
- OPFI 0.38
- MDWD N/A
- Revenue
- OPFI $260,661,000.00
- MDWD $19,720,000.00
- Revenue This Year
- OPFI N/A
- MDWD $10.15
- Revenue Next Year
- OPFI $6.51
- MDWD $25.62
- P/E Ratio
- OPFI $39.68
- MDWD N/A
- Revenue Growth
- OPFI 23.85
- MDWD N/A
- 52 Week Low
- OPFI $2.35
- MDWD $11.04
- 52 Week High
- OPFI $15.13
- MDWD $24.00
- Technical
- Relative Strength Index (RSI)
- OPFI 76.48
- MDWD 55.03
- Support Level
- OPFI $11.21
- MDWD $19.59
- Resistance Level
- OPFI $14.85
- MDWD $20.62
- Average True Range (ATR)
- OPFI 1.17
- MDWD 0.83
- MACD
- OPFI 0.17
- MDWD 0.02
- Stochastic Oscillator
- OPFI 77.48
- MDWD 54.60
About OPFI OppFi Inc.
OppFi Inc is a tech-enabled, mission-driven specialty finance platform that broadens the reach of community banks to extend credit access to everyday Americans. It recognizes revenue through finance charges on installment and SalaryTap contracts based on the interest method.
About MDWD MediWound Ltd.
MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds, and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.